The Diabetes Prevention Alliance Will Combat Diabetes in Southern States

The American Diabetes Association-Led Alliance Expands the National Diabetes Prevention Program to Reduce the Onset of Type 2 Diabetes

Translate to Spanish or other 102 languages!

The American Diabetes AssociationĀ® (ADA)Ā announced the establishment of the Diabetes Prevention Alliance (DPA), a network of stakeholder partners focused on supporting the National Diabetes Prevention Program (National DPP) and addressing social determinants of health-related health needs. Image for illustration purposes
The American Diabetes AssociationĀ® (ADA)Ā announced the establishment of the Diabetes Prevention Alliance (DPA), a network of stakeholder partners focused on supporting the National Diabetes Prevention Program (National DPP) and addressing social determinants of health-related health needs. Image for illustration purposes
- Advertisement -

The American Diabetes AssociationĀ® (ADA) announced the establishment of the Diabetes Prevention Alliance (DPA), a network of stakeholder partners focused on supporting the National Diabetes Prevention Program (National DPP) and addressing social determinants of health-related health needs.   

In 2023, the CDC awarded the ADA a five-year cooperative agreement to expand the National DPP in six states identified as part of the “Diabetes Belt”—Alabama, Florida, Louisiana, Mississippi, North Carolina, and Texas. This expansion represents a critical effort to combat the increasing rates of diabetes in these regions. The National DPP applies a proven curriculum that has been shown to reduce the risk for type 2 diabetes significantly. 

“Expanding the National DPP to these high-risk areas allows us to enhance our efforts in transforming the health of communities that are disproportionately affected by diabetes,” said Nuha El Sayed, MD, MMSc, the ADA’s senior vice president of health care improvement. “The ADA’s Diabetes Prevention Alliance will play a critical role in achieving these goals by working together to address social determinants of health and eliminating barriers to care.  We are extremely grateful for their enthusiasm and dedication to the project.” 

- Advertisement -

The ADA’s DPA is partnering with more than 40 multi-sectoral organizations to date, including health care systems, community-based organizations, National DPP delivery organizations, and payers. To date, ADA marketing efforts for the DPA have reached over 6.7 million people.  

Combining contributions from the University of Alabama Birmingham, Baylor Medical Center Houston, Fruit Street, and other dedicated organizations that are part of a network of partners, the DPA is an innovative approach to connect organizations dedicated to altering the trajectory of the diabetes epidemic and securing healthier futures for millions of Americans. 

The CDC’s investment in the ADA and three other national entities aims to improve the adoption and effectiveness of the National DPP, especially in under-resourced populations. This effort focuses on communities with historically higher risks and burdens of type 2 diabetes, including Black and Hispanic/Latino populations, as well as Americans aged 65 and older. 

Nationwide, 136 million people are living with diabetes or prediabetes, with prediabetes being the most common diagnosis. For individuals with prediabetes, participation in the program can decrease their risk of developing diabetes by up to 58% and by 71% for those aged 60 and older. 

- Advertisement -

See the list of DPA partners and join, and learn more about the ADA’s support for the implementation of the National DPP. 

Information Source: ADA

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First-of-Its-Kind Chronic Hepatitis B TreatmentĀ 

The U.S. Food and Drug Administration approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.

Why Strength Training Is Your Best Defense Against Osteoporosis

Reports show women are at higher risk for developing the bone weakening condition as they get older.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns withĀ FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

STHS Dedicating Latest “South Texas Healthy Living” Episode to Osteoporosis, Oct. 25th

Strong, healthy bones are essential to overall well-being. They support mobility, help prevent painful fractures and play a vital role in maintaining independence as we age.
- Advertisement -